Bristol Myers to partner with BioNTech on experimental cancer drug BioNTech’s drug targets both PD-L1 and VEGF, an avenue a number of biopharma companies are chasing

https://www.statnews.com/2025/06/02/bristol-myers-squibb-biontech-vegf-pdl1-bispecific-antibody-cancer/